Lipid Profile Changes in Rheumatoid Arthritis Patients: Investigation of Different Affecting Factors

  • Taraneh Dormohammadi Toosi Department of Rheumatology, University of San Diego, CA, USA. and Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. and Vali-e-Asr Hospital, Imam Khomeini Hospital Complex, Tehran, Iran.
  • Abodolrahman Rostamiyan Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. and Vali-e-Asr Hospital, Imam Khomeini Hospital Complex, Tehran, Iran.
  • Khatereh Moharrami Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. and Vali-e-Asr Hospital, Imam Khomeini Hospital Complex, Tehran, Iran.
  • Shafieh Movassaghi Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. and Vali-e-Asr Hospital, Imam Khomeini Hospital Complex, Tehran, Iran.
  • Manouchehr Nakhjavani Endocrine and Metabolic Research Center, Tehran University of Medical Sciences, Tehran, Iran.and Vali-e-Asr Hospital, Imam Khomeini Hospital Complex, Tehran, Iran
  • Amir Hossein Norooznezhad Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Keywords: Rheumatoid arthritis, Dyslipidemia, Lipid profile, Cardiovascular diseases

Abstract

It has been proved that rheumatoid arthritis (RA) is linked to dyslipidemia and the risk of cardiovascular complications is higher in these patients. The aim of this study was to evaluate dyslipidemia in RA patients. In this study, RA patients were enrolled regarding the inclusion and exclusion criteria. Their demographic information and medication profiles were evaluated. Clinical assessments were performed by evaluation of disease activity score (DAS28) and visual analogue scale. Moreover, laboratory investigations of lipid profile including triglycerides (TG), total cholesterol (Chol), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were performed. From a total of 150 patients with the mean age of 54.9±16.8 years, 65.3% were diagnosed with dyslipidemia. Females in menopausal ages had a higher prevalence of dyslipidemia as well as patients with longer disease duration. Mean serum HDL, LDL, Chol, and TG were 52.76±13.8, 96.65±21.6, 177.26±38.9, and 128.04±33.9, respectively. Considering DAS28, 100% of the patients with high disease activity were diagnosed with dyslipidemia. In the moderate and low disease activity groups and also patients in remission the ratio was 77.02%, 66.66%, and 43.75%, respectively. According to the results, patients under treatment with prednisolone and methotrexate were more affected by dyslipidemia than those with prednisolone, methotrexate, and hydroxychloroquine. Moreover, in the patients under prednisolone, methotrexate, and leflunomide treatment, the prevalence of dyslipidemia was significantly lower than those used only prednisolone and methotrexate. Altogether, it is necessary to have more clinical suspicion towards dyslipidemia and its complications in the patients with greater number of affecting factors.

References

Humphreys JH, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons DP. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis 2013;72(8):1315-20.

Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity 2017;46(2):183-96.

García-Hernández MH, González-Amaro R, Portales-Pérez DP. Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects. Immunotherapy 2014;6(5):623-636.

Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasescu R. Extra-articular manifestations in rheumatoid arthritis. Maedica (Buchar) 2010;5(4):286-291.

Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016;37(42):3232-3245.

Taleb S. Inflammation in atherosclerosis. Arch Cardiovasc Dis. 2016;109(12):708-15.

Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 2015; 11(7):390-400.

Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology 2014;53(12):2143-54.

Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. T Trends Cardiovasc Med 2017;27(2):136-140.

Naerr GW, Rein P, Saely CH, Drexel H. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascul Pharmacol 2016;81:22-30.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569-81.

Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007;66(3):407-9.

Maradit‐Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population‐based cohort study. Arthritis Rheum 2005;52(2):402-11.

Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. The Lancet 2006;368(9529):29-36.

Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment–a prospective, controlled study. Arthritis Res Ther 2006;8(3):R82.

Borman P, Seckin U, Yucel M. Dyslipidemia in patients with rheumatoid arthritis and osteoarthritis. Physc Med 1999;2(3):5-9.

Rørholm Pedersen L, Frestad D, Mide Michelsen M, Dam Mygind N, Rasmusen H, Elena Suhrs H, et al. Risk factors for myocardial infarction in women and men: a review of the current literature. Curr Pharm Des 2016;22(25):3835-52.

Nisar A, Rasheed U, Aziz W, Farooqi AZ. Prevalence of dyslipidemias in autoimmune rheumatic diseases. J Coll Physicians Surg Pak 2012;22(4):235-9.

Vijayakumar D, Suresh K, Manoharan S. Altered pattern of lipids in plasma and erythrocyte membranes of rheumatoid arthritis patients. Indian J Clin Biochem 2005;20(1):52-5.

Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009:38(5):372-81.

Lin C-P, Lin W-T, Leu H-B, Wu T-C, Chen J-W. Differential mononuclear cell activity and endothelial inflammation in coronary artery disease and cardiac syndrome X. Int J Cardiol 2003;89(1):53-62.

Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006; 33(12):2440-46.

Higashi Y, Sukhanov S, Anwar A, Shai S-Y, Delafontaine P. Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci 2012;67(6):626-39.

Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 2008; 4(3):605.

Shirinskiĭ I, Zheltova O, Shirinskiĭ V, Kozlova V. Relationship between blood lipid spectrum and activity of the disease in patients with rheumatoid arthritis. Klin Med (Mosk) 2007;86(12):40-3.

Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008;10(4):213.

Morris SJ, Wasko MCM, Antohe JL, Sartorius JA, Kirchner HL, Dancea S, et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2011;63(4):530-34.

Herink M, Ito MK. Medication Induced Changes in Lipid and Lipoproteins. In: Endotext.Edited by: De Groot LJ, Chrousos G, Dungan K, et al. MDText.com, Inc, South Dartmouth (MA); 2000.

Navarro‐Millán I, Charles‐Schoeman C, Yang S, Bathon JM, Bridges SL, Chen L, et al. Changes in lipoproteins associated with methotrexate therapy or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 2013; 65(6):1430-38.

Restrepo JF, Del Rincon I, Molina E, Battafarano DF, Escalante A. Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients. J Clin Rheumatol 2017; 23(3):144-48.

Kerr G, Aujero M, Richards J, Sayles H, Davis L, Cannon G, et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken) 2014;66(11):1619-26.

Published
2019-01-13
How to Cite
1.
Dormohammadi Toosi T, Rostamiyan A, Moharrami K, Movassaghi S, Nakhjavani M, Norooznezhad AH. Lipid Profile Changes in Rheumatoid Arthritis Patients: Investigation of Different Affecting Factors. Acta Med Iran. 56(10):665-670.
Section
Articles